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Single-cell microfluidics facilitates the rapid quantification of 
antibiotic accumulation in Gram-negative bacteria
Jehangir Camaa,b,c*†, Margaritis Voliotisa,b†, Jeremy Metza,d, Ashley Smitha,d, Jari Iannuccia,d, Ulrich 
F. Keyserc, Krasimira Tsaneva-Atanasovaa,b and Stefano Pagliaraa,d*
The double-membrane cell envelope of Gram-negative bacteria is a formidable barrier to intracellular antibiotic 
accumulation. A quantitative understanding of antibiotic transport in these cells is crucial for drug development, but this 
has proved elusive due to a dearth of suitable investigative techniques.  Here we combine microfluidics and time-lapse auto-
fluorescence microscopy to rapidly quantify antibiotic accumulation in hundreds of individual Escherichia coli cells. By serially 
manipulating the microfluidic environment, we demonstrated that stationary phase Escherichia coli, traditionally more 
refractory to antibiotics than growing cells, display reduced accumulation of the antibiotic ofloxacin compared to actively 
growing cells. Our novel microfluidic method facilitates the quantitative comparison of the role of the microenvironment 
versus various membrane transport pathways in cellular drug accumulation. Unlike traditional techniques, our assay is rapid, 
studying accumulation as the cells are dosed with the drug. This platform provides a powerful new tool for studying antibiotic 
accumulation in bacteria, which will be critical for the rational development of the next generation of antibiotics.   
Introduction
Antimicrobial resistance is recognized as a major global health 
threat, and treatment failures in patients with microbial infections 
are predicted to cause 10 million deaths annually by 20501. There is 
thus a desperate need to refresh the antibiotic development pipeline 
and develop new technologies to optimize antibiotic treatment. 
Infections caused by Gram-negative bacteria are of particular 
concern, due to the protection against antibiotics provided by the 
complex double-membrane cell envelopes of these organisms. These 
bacteria display an asymmetric outer membrane that contains 
lipopolysaccharide (LPS) molecules, which create a formidable 
permeability barrier to the cellular entry of both hydrophilic and 
hydrophobic molecules2,3. Antibiotic permeation across the outer 
membrane is therefore dependent on the drug’s ability to utilize 
protein pores (or porins)4–6, typically used for nutrient uptake, to 
circumvent this barrier. These porins show a preference for 
hydrophilic, charged compounds; however, antibiotics that are 
active against targets located in the cytoplasm have to also cross the 
inner membrane phospholipid bilayer, which acts as a selectivity 
barrier against polar, charged molecules2,3. Additionally, Gram-
negative bacteria harbor active efflux mechanisms, which pump toxic 
compounds out of the cell7. Successful drugs must minimize their 
propensity for recognition and removal by these efflux pumps, in 
addition to displaying specific physicochemical properties to 
permeate both through the outer membrane porins and inner 
membrane phospholipids2. Crucially, the expression and activity of 
porins and efflux pumps vary i) with microenvironment conditions8 
and ii) within bacteria with the same genetic make-up that are 
exposed to similar environments9. Quantitative methods for 
studying drug accumulation in individual bacteria are therefore 
crucial for understanding this molecular transport landscape, to drive 
the rational development of the next generation of antibiotics2,3.
However, the most commonly used techniques to study antibiotic 
accumulation in bacteria are population level assays which cannot 
investigate accumulation at the single-cell level; thus heterogeneity 
in transport pathways between individual cells, and any downstream 
effects on antibiotic survival are not resolvable with the majority of 
current techniques. Perhaps even more importantly, most existing 
experimental techniques suffer from the requirement of complex 
washing steps3,10, with cells only studied after resuspension in 
contrived nutrient environments11,12; the washes increase the 
chance of cell lysis and efflux or diffusion of the analyte from the 
cells3, besides affecting cellular physiology. Most available 
techniques further only provide a static picture rather than the 
dynamic evolution of drug accumulation. 
There is therefore a need to fundamentally change the experimental 
approach for quantifying antibiotic accumulation in bacteria, to 
incorporate single-cell level methodologies and the ability to study 
drug accumulation after exposure to different nutrient conditions or 
in different metabolic states. Ideally, this approach should also be 
simple to implement to ensure its uptake in pharmaceutical 
companies and in clinical settings. 
Here, we address these myriad challenges by harnessing the power 
of microfluidics and auto-fluorescence microscopy to study the 
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accumulation of the fluoroquinolone antibiotic ofloxacin in up to 
hundreds of individual bacteria confined in well-defined 
microenvironments. We require only a small aliquot of bacterial 
culture to seed a microfluidic “mother-machine” device13,14  wherein 
we accurately dose cells either in stationary or in a growing phase 
with the antibiotic. We simultaneously image ofloxacin accumulation 
in individual Escherichia coli in real-time using the auto-fluorescence 
of the drug. Since the antibiotic is itself fluorescent, we are able to 
track both drug dosage (Supplemental Note 1) and cellular 
accumulation in a label-free manner, without influencing the 
transport properties of the molecule. A number of antibiotics from 
the fluoroquinolone15 and tetracycline16,17 classes are known to be 
auto-fluorescent, and recently this property has also been observed 
in a new class of antibiotics18. Auto-fluorescence microscopy is thus 
a powerful tool for antibiotics research. Furthermore, in our 
technique there are no lysis or washing steps post drug delivery, 
which circumvents the technical challenges associated with the 
typical post-dosage handling steps described above. 
We validated our technique by studying ofloxacin accumulation in 
three E. coli strains from the Keio collection19, encompassing the 
Wild Type (WT) BW25113, an OmpF porin knockout (ompF) and a 
TolC efflux protein knockout (tolC) strain. It is noteworthy that our 
methodology enables, for what we believe is the first time, the 
direct, quantitative comparison of the role of growth phase versus 
the role of individual transport pathways in drug accumulation. We 
also complement our experimental single-cell level data with a 
mathematical model and Bayesian inference to extract details of the 
kinetics of the transport process in individual cells.
Besides its applications in drug development, our microfluidic 
platform can complement recently developed lab-on-chip antibiotic 
susceptibility testing systems to determine the contribution of 
reduced drug accumulation to bacterial survival in clinical settings20. 
Furthermore, although this study focuses on Gram-negative bacteria, 
the experimental and theoretical framework that we employ may be 
repurposed, with appropriate modifications, for advancing our 
understanding of molecular transport in a range of fundamental 
phenomena in both cellular and synthetic systems. This will pave the 
way for a direct, quantitative evaluation of the role of growth phases, 
nutrient conditions and transport pathways in drug accumulation in 
a range of cells.
Experimental
Chemicals
Chemicals were purchased from Sigma-Aldrich unless otherwise 
stated. Ofloxacin stock solutions were prepared at a concentration 
of 10 mg/ml in 1 M NaOH. For the ofloxacin accumulation 
experiments, the stock was diluted to a concentration of 12.5 g/ml 
(100×MIC) in PBS. We chose to always dissolve the ofloxacin in PBS 
to ensure that the pH conditions remained uniform during drug 
exposure across all experiments and metabolic conditions; it is well 
known that pH regulates the charge state of fluoroquinolones, which 
affects their membrane permeabilities15,21. The minimal media used 
in the experiments was prepared in sterile water and contained 
1×M9 salts, 2 mM MgSO4, 0.1 mM CaCl2 and 1 mg/L thiamine 
hydrochloride. The LB medium used for cell culture was the Melford 
high salt version containing 10 g/L casein digest peptone, 5 g/L yeast 
extract and 10 g/L NaCl; LB Agar plates were prepared with 15 g/L 
agar. Glucose stock solutions were prepared at a concentration of 0.5 
M in sterile water and diluted to 1 g/L in minimal media for use in the 
experiments. Stock solutions of bovine serum albumin (BSA) were 
prepared at a concentration of 50 mg/ml in sterile water. A stock 
solution of propidium iodide (PI) was purchased from Thermo Fisher 
Scientific, and diluted 1:1000 in PBS for use in the experiments. 
Bacterial cell culture
All the E. coli strains used were BW25113 strains purchased from the 
Keio collection. The mutant strains contained kanamycin resistance 
cassettes in place of the deleted chromosomal gene. The strains 
were stored at -80 oC in a 1:1 ratio of overnight culture and 50% 
glycerol solution. 200 ml cultures were grown in LB (with 25 g/ml 
kanamycin as necessary) at 37 oC overnight (with shaking at 200 
rpm). Streak plates were prepared on LB agar (containing 25 g/ml 
kanamycin as necessary), stored at 4 oC and used for a maximum of 
one week. 
Microfluidic chip fabrication and cell loading
The complete protocol for the fabrication of the “mother-machine” 
microfluidic devices was reported previously; these are two-layer 
microfluidic devices consisting of a “main” seeding channel (height 
25 m and width 100 m) and thousands of narrower “side-
channels” (length 25 m, height and width 1.4 m) for confining 
bacteria22. The volume of the microfluidic channel network 
(excluding the inlet and outlet columns) in the chip is on the order of 
150 nl. The epoxy mold used was constructed from replicas of 
devices kindly provided by the Jun lab14. The final devices used were 
created by pouring polydimethylsiloxane (PDMS, Dow Corning, 9:1 
base : curing agent) on to the epoxy mold; the PDMS was baked at 
70 0C for 2 h in an oven. The PDMS chips were cut out and fluidic 
inlet/outlet columns punched using a 1.5 mm biopsy punch (Miltex); 
chip heights of around 0.5-1 cm lead to inlet and outlet column 
volumes of approximately 9-18 l each. The PDMS chips were 
bonded to a type 1 coverslip using an air plasma treatment (10 s 
exposure at 30 W plasma power, Plasma etcher, Diener electronic 
GmbH, Germany) and left at 70 0C for 5 min to improve the adhesion. 
The chips were then filled with a 50 mg/ml solution of bovine serum 
albumin (BSA, in milliQ water) and incubated at 37 0C for 1 h. The BSA 
treatment passivates the internal surfaces of the chip thus 
preventing cells from adhering to the microchannels during 
experiments. 
An overnight culture of cells (OD595 typically between 4.5-5) was 
resuspended in spent LB and concentrated to an OD of 50 (at 595 
nm). The spent LB was prepared by centrifuging the overnight culture 
(10 min at 3000 g and 20 0C) – the supernatant was filtered twice 
through a 0.2 m pore filter (Millipore). An aliquot of this culture 
solution was injected into the microfluidic device and incubated at 
37 0C for 20 min, enabling cells to enter the small side channels of 
the device. The filled device was then left overnight at room 
temperature (with the inlet and outlet access ports sealed to prevent 
any evaporation) before starting experiments.
 
Microfluidic pumps
Microfluidic flows were controlled using three parallel neMESYS 
syringe pumps (Cetoni GmbH, Germany) with glass syringes (ILS, 
Germany) of volumes 5 ml, 250 l and 100 l respectively. The 
syringes were interfaced with the microfluidic chips using FEP tubing 
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(Upchurch Scientific 1520, Inner Diameter = 0.03” and Outer 
Diameter = 0.0625”). The syringes and the associated tubing were 
rinsed thoroughly with milliQ water and the appropriate 
experimental solutions before beginning the experiments, and with 
70% ethanol after completion of the experiments.   
Microscopy setup
All the experiments were performed on an Olympus IX73 
epifluorescence microscope with an LED light source (wLS pE300, 
QImaging) using a 365 nm excitation wavelength LED. The LED was 
triggered by the camera (Evolve 512 EMCCD, Photometrics) to 
ensure that the cells were only exposed to the excitation light during 
image acquisition. The camera was controlled using Manager 1.423. 
Fluorescence images were acquired using 10 ms exposure times and 
an EM gain of 200 (bin 1, clearing mode – pre-exposure).  A standard 
DAPI filter set (Chroma ET series) modified with a ZET 365/20x 
excitation filter (Chroma) was used to better match the 365 nm 
excitation wavelength. An Olympus UPLSAPO 60×W (N.A 1.2) 
objective was used for all the experiments. We used a heating stage 
(Linkam Scientific THL60-16, UK) to maintain the cells at 37 0C 
throughout the experiments. 
Drug accumulation assay
 
For both stationary phase and growing cell experiments, the cells 
were loaded onto the chip in stationary phase as described 
previously. For the experiments on growing cells, chips containing 
stationary phase E. coli were then flushed with a continuous flow of 
fresh LB (100 l/h) for 3 h using the 5 ml syringe, which led the cells 
to start growing and dividing.  At the end of this 3 h growth period, 
the LB syringe was disconnected from the chip and replaced with a 
100 l syringe containing minimal media with 1 g/L glucose, and the 
chip was flushed for 10 min (at 300 l/h) with this solution to wash 
away the LB. The glucose was added to the minimal media to prevent 
the cells from starving. Thereafter, the syringes were again 
exchanged and the ofloxacin solution (100×MIC, 12.5 g/ml 
dissolved in PBS, 250 l syringe) was perfused through the chip at 
100 l/h, with fluorescence images acquired at 5 s intervals.  The use 
of microfluidic flows and fluorescence imaging enabled us to 
precisely track the arrival of the drug in the vicinity of the cells, with 
cellular drug accumulation imaged simultaneously with drug dosage. 
It must be noted that to reduce the background auto-fluorescence at 
365 nm, prior to the ofloxacin flush the imaging area was bleached 
with the excitation light for 5 s. As detailed below, we performed 
controls  with propidium iodide staining after UV and ofloxacin 
exposure to confirm that the UV light used did not compromise the 
cells’ membrane integrity. 
For experiments on stationary phase cells, the chips containing 
stationary phase E. coli were flushed for 10 min with PBS (300 l/h) 
to wash away residual LB, the imaging area was bleached for 5 s with 
the UV light (365 nm) and subsequently the ofloxacin was perfused 
through the chip, with the drug concentration and imaging settings 
exactly the same as for the growing cell experiments. 
For both growing and stationary phase cell experiments, we 
performed auto-fluorescence controls (Supplemental Notes 2 and 3) 
where instead of the ofloxacin, PBS was perfused through the chip 
(the rest of the protocols remained identical). A representative 
dataset is reported in Figure S1 in the SI; the complete datasets of all 
the auto-fluorescence controls performed are provided as 
supplemental data.
Image Analysis
The image analysis was performed using a custom Python module24. 
First, a specified range of frames of the dataset are loaded. 
Optionally, manually selected out-of-focus time-points are ignored. 
Cell detection is performed on a frame-by-frame basis as follows. 
First the frame is filtered using a Difference-of-Gaussian (DoG) scale-
space filter25 spanning a small range of scales, corresponding to the 
scale range of bacterial widths. The resulting scale-space volume is 
maximum-projected along the scale axis, and the automatic 
threshold detected using the Triangle method26.
The centroids of the regions in the binary image resulting from 
applying this threshold are used to determine the axis of the side 
channels by using Principal Component Analysis. The axis of the side 
channels is then used to determine the upper and lower extents of 
the side-channel-region, which are then used to generate a side-
channel-region mask, in addition to two candidate main-channel-
region masks. The side-channel-region mask is then used to select 
bacterial regions from the binary image. The correct channel is 
identified from the two candidate regions by analysing the 
fluorescence for the region whose mean signal exhibits the most 
variation.
Cells are tracked frame-to-frame by matching positions such that 
nearest-matching bacteria are assigned only if the match is cross-
validated in both forward and backward temporal directions27. 
Bacterial trajectories are filtered to remove short trajectories (less 
than 10% of the full length).
The final trajectories are analysed as follows. First, a pre-determined 
dark-count (which is the average intensity of an image captured with 
the camera sensor covered) is subtracted from each bacterium's 
mean fluorescence, yielding the dark-count-corrected mean 
intensities. The corresponding dark-count-corrected PDMS 
background values for each bacterium are obtained by averaging the 
pixel intensity values of the PDMS to the immediate left and right of 
the individual bacterium and applying a similar dark-count 
correction. This bacterium-specific dark-count-corrected PDMS 
background is subtracted from the corresponding bacterium. Finally, 
the background subtracted bacterium’s intensity at the starting time 
point is subtracted from all the values at later time points, yielding 
the background corrected bacterial fluorescence profiles over the 
course of the experiment. 
For the drug dosage fluorescence, the initial intensity value of the 
dosage “main” channel (dark-count-corrected) is subtracted from all 
subsequent time points to initialise the drug fluorescence value to 0 
(before drug arrival) – this also accounts for the subtraction of the 
background in the main channel. This reveals the drug dosage 
fluorescence profile over the course of the experiment. 
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To account for any differences in absolute drug fluorescence 
between experiments, for the comparative analysis of drug 
accumulation across the different experiments, all the background 
corrected cell and drug dosage fluorescence values in an experiment 
are normalized to the final value of the drug fluorescence in the main 
channel (t = 400 s) for that experiment. Note that this drug 
fluorescence value at t = 400 s is post-subtraction of the initial main 
channel background (measured before drug arrival) and thus always 
corresponds to the same concentration of ofloxacin (100×MIC, 12.5 
g/ml) across all experiments. These values are used for all 
comparative analysis and modelling results in the paper. It is 
important to note that, since we are using this normalization in the 
model, we are assuming that the correspondence between drug 
fluorescence and concentration is the same in the main channel and 
in the vicinity of the cells. It is not possible to accurately resolve the 
drug fluorescence in the side channels in the immediate vicinity of 
each cell. The cells themselves are brighter than the surrounding 
channel and are hence easier to detect and track and, as specified 
above, we have established a protocol to subtract the scattering and 
fluorescence background for the cells. 
Finally, since the cellular auto-fluorescence profiles were flat (Figure 
S1B,D), we did not need to correct for this effect when analysing the 
drug accumulation experimental data; we simply subtracted the 
initial cellular fluorescence (at t = 0) from the cell fluorescence at all 
the time-points, as detailed above. We should also mention that the 
automated tracking works better for growing cells than for stationary 
phase cells, which were smaller in size and therefore more difficult 
to detect. However, this does not significantly affect the average 
results (Figure S2), and the cell fluorescence values obtained through 
the automated code were similar to those obtained by manually 
selecting and measuring the cells in ImageJ; since we do not fit the 
model to the data for stationary phase cells, we used the automated 
tracking results in all the figures in this manuscript. Additionally, we 
manually checked the data post the automated image analysis to 
discard certain objects that were incorrectly detected. 
Propidium Iodide (PI) staining to test membrane integrity after UV 
and ofloxacin treatment
To ensure that the combination of UV (365 nm) exposure and 
ofloxacin treatment does not compromise the cells’ membranes, we 
treated WT E. coli cells (growing) after an experiment with PI (1 l 
dissolved in 1 ml PBS) for 10 min at a flow rate of 100 l/h. PI is a 
stain commonly used to identify bacterial cells with compromised 
membranes. PI fluorescence was captured using an mCherry filter set 
(Chroma) using the green LED for excitation. A combined bright-field 
and mCherry fluorescence image representative of these 
experiments is shown in Figure S3, where it can be seen that less than 
5% of the cells are stained with PI. Similar levels of PI staining were 
obtained for cells treated with ofloxacin but not bleached directly 
with the focused UV light. This suggests that our UV exposures do 
not compromise membrane integrity for the majority (>95%) of the 
cells. 
Mathematical model
We model drug accumulation (Figure 4A) in the different 
compartments of a Gram-negative bacterium using the following set 
of ordinary differential equations (ODEs):
            (i)                            𝑉𝑀
𝑑𝐷𝑀
𝑑𝑡 = 𝑘1𝐷𝑂(𝑀0 ― 𝐷𝑀) + 𝑘1𝐷𝑃(𝑀0 ― 𝐷𝑀) ― 2𝑘2𝐷𝑀
𝑉𝑝
𝑑𝐷𝑃
𝑑𝑡 =  𝑘2𝐷𝑀 ― 𝑘1𝐷𝑃(𝑀0 ― 𝐷𝑀) ― 𝑘3𝐷𝑃 + 𝑘5𝐷𝐶 + 𝑘4𝐷𝑂 ― 𝑘4𝐷𝑃
                                                                                    (ii)― 𝑣
𝐷𝑃
𝐾𝑚 + 𝐷𝑃
                                                                  (iii)𝑉𝐶
𝑑𝐷𝐶
𝑑𝑡 = (𝑘3𝐷𝑃 ― 𝑘5𝐷𝐶) 
where , ,  and  denote the drug concentrations in the 𝐷𝑂  𝐷𝑀 𝐷𝑃 𝐷𝐶
external environment, the outer membrane, the periplasm and the 
cytoplasm, respectively. Importantly, we used the measured drug 
dosage traces for estimating  for every experiment, which allows 𝐷𝑂
us to control for any variations in the drug dosage profiles across 
different experiments. We model porin-mediated drug transport 
through the outer membrane as a two-step reversible process: drug 
molecules bind to porins with rate constant  from either side of the 𝑘1
outer membrane and unbind to either side at rate .  denotes 𝑘2 𝑀0
the concentration of functional porins in the outer membrane; based 
on literature values of the numbers of porins in typical Gram-
negative outer membranes, we assumed that the total number of 
porins would vary between approximately 1×105 to 2×105 per cell 
(WT)28; this was used to restrict the range of possible values for .  𝑀0
As a first approximation, we assume that diffusion through the LPS-
lipid bilayer is negligible  in comparison to porin-mediated (𝑘4~0)
transport3. Furthermore, we postulate that ofloxacin molecules, like 
other fluoroquinolones15,21, diffuse across the inner membrane lipid 
bilayer (rate constants  and  ) and that the efflux of drug 𝑘3 𝑘5
molecules from the periplasm to the external medium follows 
Michaelis-Menten kinetics with maximal rate  and Michaelis 𝑣
constant 29. Parameters ,  and  denote the volumes of the 𝐾𝑚 𝑉𝑀 𝑉𝑃 𝑉𝐶
outer membrane, periplasm and cytoplasm, respectively. The 
parameter  was calculated on the basis of passive diffusion 𝑘3
measurements of ofloxacin permeability across lipid vesicle bilayers 
(Figure S4). To account for any potential binding of the drug to 
targets within the cytoplasm, we do not assume any equivalence 
between  and , an approach similar to that applied by Westfall 𝑘3 𝑘5
et al.29; we only make the assumption that . Crucially, the 𝑘5 ≤ 𝑘3
parameters ( ) were inferred from the 𝑘1, 𝑘2, 𝑘5, 𝑀0,𝐾𝑚,𝑣
experimental data obtained with the WT, ompF and tolC E. coli 
strains. The total drug concentration was calculated as: 
                                                                        (iv) 𝐷𝑇 = 𝐷𝑀 ∗ 𝑉𝑀 +  𝐷𝑃 ∗ 𝑉𝑃 +  𝐷𝐶 ∗ 𝑉𝐶𝑉𝑀 + 𝑉𝑃 + 𝑉𝐶  
To model drug accumulation in the ompF strain, we used equations 
(i-iii) above, additionally assuming a possible decrease in the number 
of porins relative to the WT, i.e., . Similarly, for the 𝑀0,𝑜𝑚𝑝𝐹 ≤ 𝑀0
case of the tolC strain, we assumed that the maximal efflux rate 
may decrease relative to the WT, i.e., . 𝑣𝑡𝑜𝑙𝐶 ≤ 𝑣
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All model simulations were run in Matlab (R2018b) using the in-built 
explicit Runge-Kutta (4, 5) solver (function ode45; default settings). 
The codes are available via GitHub. Details of the parameter 
estimations and distributions are provided in the SI (Figures S5-S7).
Results 
Figure 1A explains the principle behind our drug accumulation assay.  
Geometrically confined E. coli are dosed with ofloxacin, whose 
dosage and accumulation in the cells is tracked using its auto-
fluorescence at an excitation wavelength of 365 nm. Although the 
cells themselves have a baseline auto-fluorescence before exposure 
to the drug (Figure 1B), as noted in the Experimental section, we ran 
control experiments in the absence of the drug and found that the 
auto-fluorescence profiles remain flat during the course of the 
experiment (Supplemental Note 2); this contribution is subtracted in 
our image analysis protocol. 
Figure 1. Measuring drug dosage and intracellular accumulation in 
individual bacteria. A) Schematic of the microfluidic chip used for the 
ofloxacin accumulation experiment. A main channel of height 25 m and 
width 100 m is used for continuously exchanging the microenvironment 
with nutrient, drug or dye delivery; cells are confined single-file in a network 
of side channels whose height and width are close to the cell size. B) Sequence 
of epifluorescence images (ex= 365 nm) showing the delivery of ofloxacin 
(12.5 g/ml in PBS; black rectangle) and its corresponding accumulation by 
the cells in the side channels; a representative individual cell is marked by a 
red rectangle as a guide. Scale bar = 5 m. 
It is important to emphasize that our approach allows us to precisely 
track the dosage of the drug in all our experiments, via its auto-
fluorescence (Supplemental Note 1); this allows us to study drug 
accumulation during drug dosage (Movie S1), unlike the majority of 
population level assays where the drug is typically incubated with the 
bacteria for a defined period of time before the cells are analysed12. 
Even recent single-cell approaches require bacterial pellets to first be 
incubated with drugs before being resuspended between coverslips 
for imaging30, and hence do not study drug accumulation during drug 
dosage. In contrast, our novel assay uses microfluidics to overcome 
this limitation and facilitates the real-time imaging of drug 
accumulation in response to dosage; typical single-cell fluorescence 
profiles showing the accumulation of the drug in response to the 
dose are reported in Figure 2. We observe an increase in cellular drug 
fluorescence within seconds after the arrival of the drug in the 
vicinity of the cells, which further illustrates the point that for drugs 
such as ofloxacin, accumulation studies should ideally commence as 
soon as the cells are dosed. We note that in the mother-machine, 
small molecules diffuse rapidly across the side channels, within 
approximately a second after arrival via the main channel14; thus all 
the cells in a side channel are exposed to the same drug 
concentration within a second of the drug arriving via the main 
channel.
Our cellular fluorescence profiles correlate well with a previous 
population level study of ofloxacin accumulation in E. coli that 
involved the rapid sampling of bacteria incubated with the drug –the 
study showed an initial period of rapid accumulation, within 100 
seconds31. Ofloxacin accumulation in E. coli over longer timescales of 
up to an hour appears to be biphasic31, but here we focus our 
attention on the initial stages of drug accumulation, in order to 
develop a novel assay capable of rapidly capturing the drug 
accumulation characteristics of individual cells. 
Figure 2 reports the dosage (black lines) and cellular (red lines) drug 
fluorescence profiles (normalized) of individual E. coli cells in a range 
of experiments. Comparing growing (G) versus stationary phase (S) 
Wild Type (WT) cells, we immediately observe that although the drug 
dosage profiles are similar in the two experiments, the cellular 
fluorescence (and hence drug accumulation) profiles are very 
different for stationary phase versus growing cells. We measured 
significantly lower intracellular drug fluorescence levels in stationary 
phase cells compared to cells that were growing; this also shows that 
our microfluidic technique is capable of rapidly distinguishing 
between cells that readily accumulate ofloxacin versus those that 
show a dramatically reduced accumulation profile. To quantify this 
difference, we compared the distributions of cellular fluorescence 
(normalized to the value of drug fluorescence) at t = 400 s across all 
experimental repeats in Figure 3. Over all datasets, growing WT cells 
show an approximately 3-fold higher fluorescence than stationary 
phase cells (Table 1; p<10-10; 2 sample t-test with Welch’s 
correction). A similar result was obtained when comparing growing 
and stationary phase cells in the tolC mutant strain (Table 1; p<10-
10). These differences also suggest that our fluorescence assay is not 
limited by any non-specific binding of ofloxacin to outer membrane 
components, which should be of a similar magnitude for stationary 
phase and growing cells. 
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Figure 2. Individual ofloxacin accumulation experiments for the bacterial 
strains/conditions investigated. The drug dosage plots report the temporal 
profile of ofloxacin delivery in the separate experiments, with the subsequent 
plots reporting the corresponding ofloxacin accumulation profiles of the 
individual E. coli cells; the thick red line represents the mean and the grey 
shaded area the standard deviation of the cellular ofloxacin accumulation 
profiles. The cell fluorescence values are reported after correcting for the 
background, subtracting the initial cellular auto-fluorescence at t=0, and 
normalizing to the fluorescence of the drug as detailed in the Experimental 
section. The E. coli strains (Wild Type, WT; ompF; tolC), conditions 
(growing, G; stationary phase, S) and number of cells (N) are indicated inset. 
For reference, the complete datasets (before normalization) for all 
strains/conditions including all the repeats are provided in Figure S8 in the SI.  
From Figure 2, we also observe, within a measurement timeframe of 
just 400 s, that the growing ompF mutant strain accumulates lower 
amounts of ofloxacin than the WT (growing) (Table 1; p<10-10). Thus 
knocking out the OmpF porin lowers the ability of ofloxacin to 
permeate into the cell compared to the WT strain. Our result agrees 
with previous reports that show that OmpF facilitates 
fluoroquinolone transport across Gram-negative outer 
membranes4,32. 
Table 1. Summary of the results of the normalized fluorescence 
values of cells from the different E. coli strains investigated after 
treatment with ofloxacin (at t=400 s).  
Interestingly, we were unable to detect an increase in ofloxacin 
accumulation in growing tolC mutant cells compared to the WT at 
the 400 s time-point (Figure 3). In fact, we measured a small decrease 
in the drug fluorescence in growing tolC cells compared to the 
growing WT cells (Table 1; p=2.7×10-4). 
Importantly, our ability to directly compare drug accumulation in 
different metabolic states revealed that the growing ompF mutant 
strain accumulates more ofloxacin than the stationary phase WT 
(Table 1; p<10-10), suggesting that the growth phase plays an even 
bigger role in ofloxacin accumulation than the complete removal of 
a major pathway for drug accumulation that has often been linked to 
antibiotic resistance33. We believe this is the first time such a direct 
comparison has been performed. These results emphasize the 
importance of studying the role of the cellular metabolic state in drug 
accumulation.
To further probe the transport processes underlying ofloxacin 
accumulation in individual cells, we complemented our experimental 
results with mathematical modelling, depicted schematically in 
Figure 4A (the model equations were presented earlier along with 
the experimental methods). The use of mathematical modelling and 
Bayesian inference to rationalize our data enabled us to maximize 
the information embedded in our time-lapse single-cell 
measurements, leading to predictions of the kinetics of the 
accumulation process.
We extracted kinetic parameters corresponding to the single-cell 
drug accumulation profiles and quantified changes in these 
parameters in the different strains (Figures S5A-B). To validate our 
inference procedure, we used data simulated by the model and 
showed that we can indeed recover the parameter values which 
were used for generating these (Figure S10). We used the 
parameters obtained to recapitulate the experimental drug 
accumulation trends we observed at the whole-cell level (Figure 4B). 
Note that in all our discussions of accumulation and concentrations, 
we refer to “concentrations” simply as the total number of molecules 
in a compartment (cellular or subcellular) divided by the volume of 
the compartment – hence free and bound molecules are both 
counted as contributing towards the “concentration” and 
“accumulation” in this context. 
E. coli 
strain
Growth 
phase
Number of 
cells
Normalized 
fluorescence at 
t=400 s after 
ofloxacin treatment 
(mean ± s.d.)
Wild Type Growing 317 0.34 ± 0.11
Wild Type Stationary 
phase
405 0.10 ± 0.03
ompF Growing 250 0.20 ± 0.11
tolC Growing 211 0.31 ± 0.08
tolC Stationary 
phase
193 0.12 ± 0.06
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Figure 3. Final level of normalized whole cell fluorescence for the different 
strains and nutritional conditions after exposure to ofloxacin. In the insets, 
n refers to number of experimental repeats, N reports the total number of 
bacteria and CV refers to the coefficient of variation of the data across all the 
experiments for a given strain and condition. All comparisons are made at t = 
400 s. To ease comparisons between the strains/conditions, a box plot 
summarising the data from the distributions above is provided in Figure S9.  
The model also allowed us to predict drug accumulation in the 
different subcellular compartments (Figure S5C), which is a major 
challenge for the entire research community working on this 
problem (the detailed predictions are described in the SI). Briefly, the 
model predicts that the periplasm contains approximately 30-fold 
lower ofloxacin concentrations than the cytoplasm for all three 
strains at t = 400 s – this is likely due to the binding of the ofloxacin 
molecules to targets within the cytoplasm. The model also predicts a 
lag time of approximately 100 s between drug accumulation in the 
outer membrane versus drug accumulation in the cytoplasm. It is 
important to note that these are predictions, arising out of our 
whole-cell data; validation of the model predictions regarding 
subcellular levels of drug concentration will only be possible once the 
considerable experimental challenges for these measurements are 
overcome. Future work will also involve studying drug accumulation 
after modulation of other transport pathways in the Gram-negative 
double membrane to estimate their relative contributions to drug 
accumulation at the subcellular level. 
Figure 4. Mathematical modelling of the drug transport process. A) 
Schematic of the main processes involved in drug translocation across Gram-
negative cell envelopes. Drug molecules penetrate the outer membrane (M) 
primarily through protein porins, with association and dissociation rates  𝑘1
and , respectively.  refers to the concentration of functional porin 𝑘2 𝑀0
binding sites in the outer membrane. Any residual (non-porin) transport 
across the outer membrane LPS barrier is modelled with . Drug transport 𝑘4
through the inner membrane is modelled with kinetic parameters  and . 𝑘3 𝑘5
Drug molecules are subject to removal from the cell via active efflux 
mechanisms which follow Michaelis-Menten kinetics ( ). B) The temporal 𝐾𝑚, 𝑣
dependence of the normalized drug concentration in cells for WT (red), 
ompF (blue) and tolC (green) bacteria in response to the drug dosage input 
(dashed black line) is in line with the experimental results on growing cells. 
Note that the “concentrations” here include both free and bound drug 
molecules. These drug accumulation profiles were obtained by using the 
kinetic parameter values in Figures S5A and S5B and the theoretical model 
(equations (i)-(iii)). The concentrations reported are normalized to the drug 
dosage concentration. The solid lines correspond to median accumulation in 
the cells and the dashed lines represent the [20,80] posterior predictive 
intervals. The results shown were generated by running the model using 500 
independent samples of parameters  and  from their joint posterior 𝑀′0 𝑣′
distributions (details in SI). All other parameters were fixed to the values given 
in Table S2. 
Discussion
Antibiotic accumulation in Gram-negative bacteria is an extremely 
complex biophysical phenomenon because of the different 
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physicochemical pathways and combination of active and passive 
transport processes involved. It is essential to understand the roles 
of these pathways in a quantitative manner to rationally design drugs 
that can accumulate in the vicinity of their targets, which will crucially 
contribute to overcoming the void in Gram-negative drug discovery. 
This has proved exceptionally challenging, in part due to the lack of 
investigative techniques that can study these processes in well-
controlled environments, with single-cell resolution.
We have leveraged the power of microfluidics to develop a rapid, 
single-cell assay to quantify antibiotic accumulation in Gram-
negative bacteria. We demonstrated that we can distinguish 
between cells that show dramatically different drug accumulation 
profiles within measurement timescales of under 400 s. This 
complements the recent drive towards rapid antibiotic susceptibility 
tests that can inform on the susceptibility of pathogenic bacteria to 
antibiotics within 30 minutes, as opposed to traditional minimum 
inhibitory concentration studies that typically take hours to days to 
provide results20; such rapid testing is critically important in clinical 
settings. Unlike the majority of techniques, which involve complex 
washing steps after drug delivery, or are limited to certain specific 
media conditions3,10, our microfluidic platform facilitates the study 
of drug accumulation in different microenvironments and cellular 
metabolic states. We quantify drug dosage in every experiment, 
which allows us to correct for any variations in fluorescence 
intensities/flow conditions between experiments. Since we use 
microfluidics, we quantify drug accumulation from the moment the 
drug arrives in the vicinity of the cells, facilitating the real-time 
measurement of the transport process. 
Furthermore, since our excitation wavelength is 365 nm 
(Supplemental Note 4), in contrast to previous studies using deep UV 
illumination to study antibiotic accumulation in single cells11,34, we 
can work with standard optics and light sources, rather than needing 
quartz objectives and cover slips, and deep UV light sources which 
may not be easily accessible, thus facilitating the use of our assay in 
non-specialized laboratories. 
Using our novel approach, we established that within the timescales 
investigated, ofloxacin accumulates to a greater degree in growing 
versus stationary phase bacteria (Figures 2 and 3). It is likely that this 
reduction in ofloxacin accumulation contributes to the significant 
increase in cell survival to this drug that was previously observed as 
the cells enter stationary phase compared with early exponential 
phase cultures35,36, since ofloxacin’s antibacterial activity depends on 
its accumulation in the cytoplasm of the bacteria. It is interesting to 
speculate on whether this difference in accumulation is mediated by 
differences in the expression of the target or whether it is due to 
differences in the expression of the drug transport pathways. 
Fluoroquinolone antibiotics target DNA gyrase and particularly its 
complexes with DNA37,38, which regulate DNA supercoiling. The levels 
of the Gyr proteins themselves do not change appreciably as cells 
grow from exponential into stationary phase, even after 72 h of 
starvation39. However, quantifying the levels of DNA gyrase-DNA 
complexes is more difficult; the fact that stationary phase cells 
display a distribution of relaxed (as opposed to supercoiled) plasmids 
suggests that the levels of DNA gyrase-DNA complexes decrease as 
cells progress into stationary phase39, which could explain the 
differences in drug accumulation between the states. We note that 
these DNA gyrase-DNA complexes (and potentially other intracellular 
components) act as a sink for the ofloxacin molecules once they 
enter the cell, which explains the higher fluorescence of the cells 
compared to the background observed post drug exposure in Figure 
1B. 
On the other hand, transcriptomic studies have also revealed that 
the expression of the genes encoding the major E. coli porins OmpF 
and LamB, through which antibiotics diffuse, was significantly 
upregulated in exponentially growing compared to stationary phase 
E. coli cells (Figure S1135). This suggests that the differences in 
ofloxacin accumulation that we observe between growing and 
stationary phase cells may also be due to phenotypic modifications 
of the cell envelope transport pathways. However, this will require 
further investigation. Future studies on the differences in 
accumulation between cells in different physiological states may also 
contribute towards a better understanding of antibiotic tolerance; 
indeed, it is known that growth conditions play an important role in 
the development of tolerance to various antibiotic classes40. The 
technique presented in this paper offers a platform for the 
investigation of these observations in the context of differential drug 
uptake, complementing efforts to characterize phenotypic 
heterogeneity such as antibiotic tolerance and persistence9,41–44. 
 
Using biophysical experimental model systems, we and others have 
previously shown in vitro that porins such as OmpF facilitate 
fluoroquinolone transport across the outer membrane5,32, and that 
fluoroquinolones also diffuse freely across phospholipid bilayers 
such as those found in the cytoplasmic membrane15. In our 
experiments on growing cells, knocking out the ompF gene led to a 
decrease in drug accumulation compared to the WT strain, 
confirming that fluoroquinolones utilize porins to enter E. coli cells. 
However, the effect of the growth phase was more significant than 
the removal of the porin – stationary phase WT cells accumulated 
significantly lower amounts of ofloxacin than the growing ompF 
mutant (Figures 3, S9). Previous studies have reported that nutrient-
starved bacteria show reduced drug accumulation45, but these 
studies did not determine the extent to which environmental factors, 
and subsequent cell phenotypic acclimation, predetermine drug 
accumulation compared to genotypic changes which result in protein 
loss.
On the other hand, the role of the TolC efflux protein in 
fluoroquinolone transport is currently a matter of debate. As 
described in the Results, we did not measure any increase in drug 
accumulation in the tolC strain, compared to the WT strain (growing 
cells). The TolC outer membrane efflux protein forms an important 
part of multi-drug efflux systems such as AcrAB-TolC that eject 
antibiotics and other toxins from E. coli cells46, and naively one would 
have expected that losing TolC negatively affects the ability of the 
cell to efflux the antibiotic, thus increasing its intracellular 
accumulation. However, cellular fluoroquinolone accumulation data 
comparing parental WT strains and their corresponding tolC 
knockouts show contradictions, with some reports showing 
increased accumulation47 in the knockout and others showing no 
significant differences between the strains48. Further, although the 
overproduction of the AcrAB-TolC efflux system has been implicated 
in the antibiotic resistance of clinical isolates of E. coli species, there 
was no significant correlation between the overexpression of the 
acrAB and tolC genes46,49. With regards to fluoroquinolone 
antibiotics, it was reported that average tolC expression levels in 
fluoroquinolone-susceptible and fluoroquinolone-resistant clinical 
isolates of E. coli were not statistically different46,49. Zgurskaya and 
co-workers therefore concluded that TolC quantities alone do not 
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limit the drug efflux capabilities of E. coli46. Our data further 
corroborate this hypothesis. 
In terms of future developments (Supplemental Note 5), our 
microfluidic approach offers possibilities for scaling up the number 
of drugs/pathogens that can be tested on the same chip, via 
parallelization of the cell trapping chambers.  On the drug 
development side, the assay also has the advantage of needing only 
micrograms of chemicals for testing, which is important when 
evaluating novel, candidate drugs that are typically expensive to 
manufacture. Our readout is based on fluorescence, and can be used 
to test the cell permeation properties of new fluorescent antibiotic 
probes that have been developed for a range of antibiotics including 
penicillins, glycopeptides, polymixins, oxazolidinones, trimethoprim, 
macrolides and fluoroquinolones50–54; similar probes can be 
developed for newly discovered antimicrobials as well. The use of 
more sensitive fluorescent probes could also let us potentially 
correlate cell survival to reduced accumulation in longer-term 
experiments in the future. Our assay could also be used to study the 
influence of specific functional groups on the cellular accumulation 
of closely related compounds. For instance, biophysical 
measurements of different fluoroquinolones revealed orders of 
magnitude differences in their lipid permeabilities15; our system 
facilitates similar studies on the bacteria themselves. 
Conclusions
We have developed a novel approach to investigate antibiotic 
accumulation in individual Gram-negative bacteria in well-controlled 
microenvironments. Our experiments enabled us to quantify the role 
of the nutrient microenvironment and metabolic state of the cells in 
drug accumulation at the single-cell level. We reported, to the best 
of our knowledge, the first quantitative comparisons between drug 
accumulation in cells in different metabolic states and in cells with 
specific transport pathways disabled. Combining our data with 
mathematical modelling and Bayesian inference enabled us to 
predict the kinetic parameters underlying ofloxacin accumulation in 
individual E. coli cells. As discussed, our technology represents a 
step-change in the way drug accumulation in bacteria is studied, with 
potential benefits to the drug development and diagnostics 
industries, infectious disease specialists, as well as to the large 
academic community studying antibiotic transport in Gram-negative 
organisms. The experimental setup is relatively simple to implement 
on standard epi-fluorescence microscopes and will provide 
researchers with a new, transferrable platform with which to study 
this vitally important permeation process in a range of pathogenic 
microbes. 
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